Springer Nature
Browse
13073_2017_436_MOESM11_ESM.docx (12.72 kB)

Additional file 11: of A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

Download (12.72 kB)
journal contribution
posted on 2017-05-31, 05:00 authored by Colin Ross, Fadi Towfic, Jyoti Shankar, Daphna Laifenfeld, Mathis Thoma, Matthew Davis, Brian Weiner, Rebecca Kusko, Ben Zeskind, Volker Knappertz, Iris Grossman, Michael Hayden
Change in ARR among placebo patients who were switched to Copaxone treatment in the OL phase. (DOCX 12 kb)

Funding

Teva Pharmaceutical Industries (IL)

History